Phase 2 trial of brentuximab vedotin plus AVD for limited-stage Hodgkin lymphoma | Dr Jeremy Abramson at Annual Meeting 2015

Phase 2 trial of brentuximab vedotin plus AVD for limited-stage Hodgkin lymphoma | Dr Jeremy Abramson at Annual Meeting 2015

EMJ

4 years
710 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses a multicentre phase 2 study, which is evaluating brentuximab vedotin plus adriamycin, vinblastine and dacarbazine (AVD) for patients with non-bulky limited-stage Hodgkin lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay